Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Patterns of Interstitial Lung Disease in Egyptian Patients with Systemic Sclerosis: Relation to Disease Parameters

Author(s): Abeer Ali Abdelati*, Akram Abd-Elmonaem Deghady, Ahmed Mohamed Abdelhady, Rim Aly Bastawy and Ahmed Shaaban

Volume 19, Issue 2, 2023

Published on: 03 September, 2022

Page: [189 - 196] Pages: 8

DOI: 10.2174/1573397118666220818095927

Price: $65

Abstract

Background: Pulmonary involvement is the most common leading cause of morbidity and mortality associated with systemic sclerosis. Therefore, identifying the various patterns of pulmonary affection is crucial in the clinical management of these patients. In the current study, we aim to investigate the patterns of interstitial lung disease (ILD) associated with SSc patients (SSc- ILD) and their relation to serologic markers and clinical parameters.

Methods: A cross-sectional study was undertaken on thirty-four adult SSc patients who met the 2013 ACR/EULAR criteria for SSc and Forty healthy controls of matched age and sex. The patients were subjected to history taking, clinical examination, skin assessment using the modified Rodnan Skin Score (mRSS), chest x-ray (CXR), pulmonary function test (PFTs), and high resolution computed tomography of the chest (HRCT). Routine laboratory tests were conducted in addition to immunologic tests and an enzyme-linked immunosorbent assay (ELISA) to determine the IL-33 level.

Results: ILD was found in 23 SSc patients (67.6%); 20 patients had diffuse type while 3 patients had limited type. Non-specific interstitial pneumonia (NSIP) was found in 56.5%, usual interstitial pneumonia (UIP) was found in 21.7%, pleuroparenchymal fibroelastosis (PPFE) was found in 8.7%, and organizing pneumonia (OP) with the mixed pattern was found in 13% of SSc patients. Additionally, the mean IL-33 level in SSc patients was 98±12.7 compared to 66.2±10.6 in the control group (p < 0.001), with ILD patients having a significantly higher level (101.7±13.4) than those without (90.4±6.2), and a strong positive correlation with mRSS.

Conclusion: Even in asymptomatic patients with SSc, ILD is prevalent, with NSIP being the most common pattern. IL-33 could be considered a potential biomarker for predicting the presence of ILD in SSc patients.

Keywords: Systemic sclerosis, interstitial, HRCT, interleukin-33, pneumonia, pleuroparenchymal fibroelastosis.

« Previous Next »
[1]
Varga J. Systemic sclerosis: An update. Bull NYU Hosp Jt Dis 2008; 66(3): 198-202.
[PMID: 18937632]
[2]
Nihtyanova SI, Ong VH, Denton CP. Current management strategies for systemic sclerosis. Clin Exp Rheumatol 2014; 32(2) (Suppl. 81): 156-64.
[PMID: 24742450]
[3]
Wells AU, Steen V, Valentini G. Pulmonary complications: One of the most challenging complications of systemic sclerosis. Rheumatology (Oxford) 2009; 48 (Suppl. 3): iii40-4.
[http://dx.doi.org/10.1093/rheumatology/kep109] [PMID: 19487223]
[4]
Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G. Scleroderma lung disease. Eur Respir Rev 2013; 22(127): 6-19.
[http://dx.doi.org/10.1183/09059180.00005512] [PMID: 23457159]
[5]
Minai OA, Dweik RA, Arroliga AC. Manifestations of scleroderma pulmonary disease. Clin Chest Med 1998; 19(4): 713-31.
[http://dx.doi.org/10.1016/S0272-5231(05)70112-X] [PMID: 9917962]
[6]
Gohari Moghadam K, Gharibdoost F, Parastandechehr G, Salehian P. Assessments of pulmonary involvement in patients with systemic sclerosis. Arch Iran Med 2011; 14(1): 22-6.
[PMID: 21194257]
[7]
Wells AU. High resolution computed tomography and scleroderma lung disease. Heumatology (Oxford) 2008; 47(5): v59-61.
[8]
Goh NS, Bois RM. Interstitial disease in systemic sclerosis. In: Wells AU, Denton CP, Eds. Handbook of systemic autoimmune diseases. (1st ed.). Amsterdam, The Netherlands: Elsevier 2004; pp. 181-207.
[9]
White B. Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am 1996; 22(4): 695-708.
[http://dx.doi.org/10.1016/S0889-857X(05)70296-9] [PMID: 8923591]
[10]
Postlethwaite AE. Role of T cells and cytokines in effecting fibrosis. Int Rev Immunol 1995; 12(2-4): 247-58.
[http://dx.doi.org/10.3109/08830189509056716] [PMID: 7650423]
[11]
Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: A novel ‘alarmin’? PLoS One 2008; 3(10): e3331.
[http://dx.doi.org/10.1371/journal.pone.0003331] [PMID: 18836528]
[12]
Wei J, Zhao J, Schrott V, et al. Red blood cells store and release interleukin-33. J Investig Med 2015; 63(6): 806-10.
[http://dx.doi.org/10.1097/JIM.0000000000000213] [PMID: 26107423]
[13]
Bertheloot D, Latz E. HMGB1, IL-1α IL-33 and S100 proteins: Dual function alarmins. Cell Mol Immunol 2017; 14(1): 43-64.
[http://dx.doi.org/10.1038/cmi.2016.34] [PMID: 27569562]
[14]
Torok KS, Kurzinski K, Kelsey C, et al. Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T helper cell associated cytokine profiles. Semin Arthritis Rheum 2015; 45(3): 284-93.
[http://dx.doi.org/10.1016/j.semarthrit.2015.06.006] [PMID: 26254121]
[15]
Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65(11): 2737-47.
[http://dx.doi.org/10.1002/art.38098] [PMID: 24122180]
[16]
Khanna D, Furst DE, Clements PJ, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord 2017; 2(1): 11-8.
[http://dx.doi.org/10.5301/jsrd.5000231] [PMID: 28516167]
[17]
Hong YS, Moon SJ, Joo YB, et al. Measurement of interleukin-33 (IL-33) and IL-33 receptors (SST2 AND ST2L) in patients with rheumatoid arthritis. J Korean Med Sci 2011; 26(9): 1132-9.
[http://dx.doi.org/10.3346/jkms.2011.26.9.1132] [PMID: 21935266]
[18]
Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, et al. An official European Respiratory Society/American Thoracic Society research statement: Interstitial pneumonia with autoimmune features. Eur Respir J 2015; 46: 976-87.
[http://dx.doi.org/10.1183/13993003.00150-2015]
[19]
Desai SR, Veeraraghavan S, Hansell DM, et al. CT features of lung disease in patients with systemic sclerosis: Comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004; 232(2): 560-7.
[http://dx.doi.org/10.1148/radiol.2322031223] [PMID: 15286324]
[20]
Kirkpatrick LA, Feeney BC. A simple guide to IBM SPSS statistics for version 20.0. Belmont, California: Wadsworth, Cengage Learning 2013.
[21]
Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69(10): 1809-15.
[http://dx.doi.org/10.1136/ard.2009.114264] [PMID: 20551155]
[22]
Kim EA, Lee KS, Johkoh T, et al. Interstitial lung diseases associated with collagen vascular diseases: Radiologic and histopathologic findings. Radiographics 2002; 22: S151-65.
[http://dx.doi.org/10.1148/radiographics.22.suppl_1.g02oc04s151] [PMID: 12376608]
[23]
Russell S, Marie H, Ernest L, Murray B. Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res 2011; 64(4): 519-24.
[24]
Hafez EA, Hamza SH, Morad CS, Abd Alkader AA. Pulmonary manifestations in Egyptian patients with systemic sclerosis. Egypt Rheumatol 2018; 40(1): 39-44.
[http://dx.doi.org/10.1016/j.ejr.2017.06.004]
[25]
Mohamad N, Sophie L, Loic B, Salim SM, Fabienne B, Sébastien M. Prevalence and mortality of systemic sclerosis-associated interstitial lung disease (SSc-ILD) using the French national health insurance system (SNDS) database in France. Eur Respir J 2020; 56: 805.
[http://dx.doi.org/10.1183/13993003]
[26]
Shah RM, Jimenez S, Wechsler R. Significance of ground-glass opacity on HRCT in long-term follow up of patients with systemic sclerosis. J Thorac Imaging 2007; 22(2): 120-4.
[http://dx.doi.org/10.1097/01.rti.0000213572.16904.40] [PMID: 17527113]
[27]
Molberg Ø, Hoffmann AM. Interstitial lung disease in systemic sclerosis: Progress in screening and early diagnosis. Curr Opin Rheumatol 2016; 28(6): 613-8.
[http://dx.doi.org/10.1097/BOR.0000000000000323] [PMID: 27387267]
[28]
Bernstein EJ, Khanna D, Lederer DJ. Screening high resolution computed tomography of the chest to detect interstitial lung disease in systemic sclerosis: A global survey of rheumatologists. Arthritis Rheumatol 2018; 70(6): 971-2.
[http://dx.doi.org/10.1002/art.40441] [PMID: 29426066]
[29]
Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188(6): 733-48.
[http://dx.doi.org/10.1164/rccm.201308-1483ST] [PMID: 24032382]
[30]
Enomoto Y, Nakamura Y, Colby TV, et al. Radiologic pleuroparenchymal fibroelastosis like lesion in connective tissue disease related interstitial lung disease. PLoS One 2017; 12(6): e0180283.
[http://dx.doi.org/10.1371/journal.pone.0180283] [PMID: 28666014]
[31]
Watanabe K, Nagata N, Kitasato Y, et al. Rapid decrease in forced vital capacity in patients with idiopathic pulmonary upper lobe fibrosis. Respir Investig 2012; 50(3): 88-97.
[http://dx.doi.org/10.1016/j.resinv.2012.06.003] [PMID: 23021767]
[32]
Taylor JG, Bolster MB. Bronchiolitis obliterans with organizing pneumonia associated with scleroderma and scleroderma spectrum diseases. J Clin Rheumatol 2003; 9(4): 239-45.
[http://dx.doi.org/10.1097/01.rhu.0000083860.27509.f1] [PMID: 17041464]
[33]
Yanaba K, Yoshizaki A, Asano Y, Kadono T, Sato S. Serum IL-33 levels are raised in patients with systemic sclerosis: Association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin Rheumatol 2011; 30(6): 825-30.
[http://dx.doi.org/10.1007/s10067-011-1686-5] [PMID: 21246230]
[34]
Li L, Zhu H, Zuo X. Interleukin-33 in systemic sclerosis: Expression and pathogenesis. Front Immunol 2018; 9: 2663.
[http://dx.doi.org/10.3389/fimmu.2018.02663] [PMID: 30498500]
[35]
Groseanu L, Petrescu S, Balanescu A, et al. Do we have good activity indices in systemic sclerosis? Curr Rheumatol Rev 2022; 18(1): 39-47.
[http://dx.doi.org/10.2174/1573397117666210913102759] [PMID: 34517805]
[36]
Vettori S, Cuomo G, Iudici M, et al. Early systemic sclerosis: Serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels. J Clin Immunol 2014; 34(6): 663-8.
[http://dx.doi.org/10.1007/s10875-014-0037-0] [PMID: 24760110]
[37]
Kakkar R, Hei H, Dobner S, Lee RT. Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J Biol Chem 2012; 287(9): 6941-8.
[http://dx.doi.org/10.1074/jbc.M111.298703] [PMID: 22215666]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy